Compounded sustained-release buprenorphine (SRB) has historically been used at our institution for postoperative analgesia in African green monkeys (AGMs), but it is not FDA approved and lacks species-specific data. With the recent FDA indexing of pharmaceutical-grade extended-release buprenorphine (EXR; Ethiqa XR; Fidelis), we aimed to compare the pharmacokinetic (PK) profile using serial plasma sampling up to 96 hours and postoperative analgesic efficacy of EXR compared with SRB. A total of 10 AGMs (n = 5 per test article) received 0.2 mg/kg SC of either EXR or SRB to complete the PK study. For the efficacy study, 20 animals (n = 10 per test article) were monitored for 3 days postoperatively after EEG telemetry surgery with femoral artery catheterization for behavioral indicators of pain and adverse effects. Plasma buprenorphine levels were analyzed using liquid chromatography-tandem mass spectrometry. PK study observations included appetite, fecal output, and injection site reactions. Both formulations achieved plasma concentrations above the presumed therapeutic threshold (0.1 ng/mL) for up to 96 hours. SRB produced higher mean plasma levels at early time points (30 minutes, 4 hours), but the overall PK profiles were similar. Injection site reactions were minimal and resolved spontaneously. For the efficacy assessment, clinical observations were evaluated using a postoperative score sheet. No significant differences were observed in postoperative pain scores between groups. Both EXR and SRB at 0.2 mg/kg SC provided sustained therapeutic plasma levels up to 96 hours and were well tolerated in AGMs, with comparable efficacy in postoperative pain control. EXR offers a compliant and effective alternative to compounded SRB for analgesia in AGMs, supporting its use in laboratory settings and regulatory compliance with current guidelines.
Brown et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: